Alyeska Investment Group L.P. Invests $2.50 Million in Oculis Holding AG $OCS

Key Points

• Alyeska Investment Group L.P. has acquired 131,332 shares of Oculis Holding AG, valued at approximately $2.5 million, representing a 0.30% ownership stake in the company.
• Institutional investors currently hold 22.30% of Oculis, with notable increases in holdings from entities like Bank of America and Pivotal bioVenture Partners in recent quarters.
• Analysts maintain a positive outlook on Oculis, with an average rating of "Buy" and a target price of $35.75 following recent upgrades, including recommendations from Needham & Company and Chardan Capital.

Alyeska Investment Group L.P. bought a new stake in Oculis Holding AG (NASDAQ:OCS - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 131,332 shares of the company's stock, valued at approximately $2,499,000. Alyeska Investment Group L.P. owned about 0.30% of Oculis at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in OCS. Pivotal bioVenture Partners Investment Advisor LLC grew its position in Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company's stock worth $43,784,000 after buying an additional 563,078 shares in the last quarter. Aberdeen Group plc grew its holdings in shares of Oculis by 24.1% during the 1st quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock worth $23,847,000 after purchasing an additional 243,695 shares in the last quarter. SR One Capital Management LP acquired a new stake in shares of Oculis during the 1st quarter worth $6,137,000. Bank of America Corp DE increased its position in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after purchasing an additional 10,667 shares during the period. Finally, Citadel Advisors LLC acquired a new position in Oculis in the fourth quarter valued at about $389,000. 22.30% of the stock is owned by institutional investors and hedge funds.

Oculis Stock Performance

Shares of NASDAQ OCS traded down $0.01 during midday trading on Thursday, reaching $17.22. The company's stock had a trading volume of 18,068 shares, compared to its average volume of 12,748. The stock has a market capitalization of $751.86 million, a P/E ratio of -6.45 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.55 and a quick ratio of 4.55. The firm has a 50 day moving average price of $17.70 and a 200-day moving average price of $18.26. Oculis Holding AG has a 12-month low of $11.78 and a 12-month high of $23.08.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Thursday, August 21st. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.06). The business had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative return on equity of 90.31% and a negative net margin of 13,958.12%. As a group, equities analysts predict that Oculis Holding AG will post -2.09 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Needham & Company LLC initiated coverage on shares of Oculis in a report on Wednesday, August 27th. They issued a "buy" rating and a $36.00 target price on the stock. HC Wainwright lifted their price objective on shares of Oculis from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, August 22nd. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $35.75.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.